Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarkers to Enhance Early Schizophrenia Treatment

NCT06969755 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT06969755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06969755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarkers to Enhance Early Schizophrenia Treatment
Lead sponsor
Northwell Health
Phase
Phase 4
Overall status
Recruiting
Start date
September 4, 2024
Completion date
July 30, 2030
Enrollment
180 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

schizophenia disorder